AstraZeneca's Tagrisso Cuts Death Risk 47% in Long-Term Lung Cancer Trial
核心洞察
Updated ADAURA results show adjuvant Tagrisso reduced death risk by 47% versus placebo in Stage II to IIIA EGFR (搜索)-mutated non-small cell lung cancer (搜索).
Estimated eight-year survival was 74% with Tagrisso versus 58% with placebo in the primary population, with a hazard ratio of 0.53.
In the broader Stage IB to IIIA population, Tagrisso cut death risk by 48%, with 79% versus 64% estimated eight-year survival.
AstraZeneca reported updated exploratory overall survival results from the Phase III ADAURA trial showing adjuvant Tagrisso (osimertinib) maintained a survival benefit eight years after treatment in early-stage EGFR (搜索)-mutated non-small cell lung cancer (搜索). In the trial's primary population of patients with Stage II to IIIA disease, Tagrisso reduced the risk of death by 47% compared with placebo, with a hazard ratio of 0.53 (95% CI 0.38 to 0.75). An estimated 74% of Tagrisso-treated patients in that group were alive at eight years versus 58% of those who received placebo.
Across the broader Stage IB through IIIA population, Tagrisso reduced the risk of death by 48%, with a hazard ratio of 0.52 (95% CI 0.39 to 0.71) and estimated eight-year survival of 79% versus 64% for placebo. The data were presented at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer in Seoul and published simultaneously in the Journal of Thoracic Oncology. AstraZeneca described the follow-up as the longest survival data reported from a global Phase III trial in this adjuvant setting. The overall survival benefit was observed across all predefined subgroups, and final safety data showed no new safety concerns.
Separate real-world evidence presented at the conference examined U.S. patients with Stage I to IIIA EGFRm non-small cell lung cancer (搜索) and found that discontinuing Tagrisso before completing the three-year course was associated with more than twice the risk of disease recurrence or death. AstraZeneca also presented longer-term FLAURA2 Phase III findings in first-line advanced EGFRm disease: after a median 42.6 months of follow-up, Tagrisso plus platinum-pemetrexed chemotherapy showed safety and tolerability consistent with the established profiles of the treatments, with fewer new adverse events after the induction period. An exploratory analysis found progression-free and overall survival hazard ratios numerically favored the combination over Tagrisso alone regardless of baseline TP53 (搜索) co-mutation status.